Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

Core Insights - Bavarian Nordic A/S has received notification from Morgan Stanley regarding their shareholding, which stands at 5.20% of the shares and voting rights as of October 23, 2025 [1] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [2] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness [2] - Bavarian Nordic also has a leading portfolio of travel vaccines [2]